Tamsulosin Potently and Selectively Antagonizes Human Recombinant .ALPHA.1A/1D-Adrenoceptors: Slow Dissociation from the .ALPHA.1A-Adrenoceptor May Account for Selectivity for .ALPHA.1A-Adrenoceptor over .ALPHA.1B-Adrenoceptor Subtype
スポンサーリンク
概要
- 論文の詳細を見る
We determined the binding affinity of tamsulosin, a selective α1-adrenoceptor antagonist, for human α1-adrenoceptor subtypes in comparison with those of other α1-adrenoceptor antagonists including silodosin, prazosin, 5-methylurapidil, terazosin, alfuzosin, nafopidil, urapidil and BMY7378. The association and dissociation kinetics of [3H]tamsulosin for recombinant human α1-adrenoceptor subtypes were compared with those of [3H]prazosin. Tamsulosin competitively inhibited [3H]prazosin binding to human α1A-, α1B- and α1D-adrenoceptors (pKi values were 10.38, 9.33, 9.85) indicating 11 and 3.4-fold higher affinities for human α1A-adrenoceptor than those for α1B- and α1D-adrenoceptors, respectively. The affinity of tamsulosin for the human α1A-adrenoceptor was, respectively, 5, 9.9, 38, 120, 280, 400, 1200 and 10000 fold higher than those of silodosin, prazosin, 5-methylurapidil, terazosin, alfuzosin, naftopidil, urapidil and BMY7378, respectively. [3H]Tamsulosin dissociated from the α1A-adrenoceptor slower than from the α1B- and α1D-adrenoceptors (α1B>α1D>α1A). Moreover, [3H]tamsulosin dissociated slower than [3H]prazosin from the α1A-adrenoceptor and faster from the α1B- and α1D-adrenoceptors. In conclusion, tamsulosin potently and selectively antagonized α1A/1D-adrenoceptor ligand binding, and slowly dissociated from the α1A-adrenoceptor subtype.
著者
-
SASAMATA Masao
Applied Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc.
-
Yuyama Hironori
Pharmacology Research Labs. Drug Discovery Research Astellas Pharma Inc.
-
Hatanaka Toshiki
Pharmacology Research Labs. Drug Discovery Research Astellas Pharma Inc.
-
Sato Shuichi
Applied Pharmacology Research Laboratories Drug Discovery Research Astellas Pharma Inc.
-
Ohtake Akiyoshi
Applied Pharmacology Research Laboratories Drug Discovery Research Astellas Pharma Inc.
-
Sasamata Masao
Applied Pharmacology Res. Laboratories Drug Discovery Res. Astellas Pharma Inc.
-
Miyata Keiji
Applied Pharmacology Res. Laboratories Drug Discovery Res. Astellas Pharma Inc.
-
Ukai Masashi
Applied Pharmacology Res. Laboratories Drug Discovery Res. Astellas Pharma Inc.
-
Hatanaka Toshiki
Applied Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc.
-
Noguchi Yukiko
Applied Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc.
-
Taguchi Katsunari
Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc.
-
Noguchi Yukiko
Applied Pharmacology Res. Laboratories Drug Discovery Res. Astellas Pharma Inc.
-
Ohtake Akiyoshi
Applied Pharmacology Res. Laboratories Drug Discovery Res. Astellas Pharma Inc.
-
Ukai Masashi
Applied Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc.
-
Yuyama Hironori
Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc.
関連論文
- New Topics in Vasopressin Receptors and Approach to Novel Drugs : Research and Development of Conivaptan Hydrochloride (YM087), a Drug for the Treatment of Hyponatremia
- Pharmacological Characterization of a New Antimuscarinic Agent, Solifenacin Succinate, in Comparison with Other Antimuscarinic Agents(Pharmacology)
- Effects of Intravenously and Orally Administered Solifenacin Succinate (YM905) on Carbachol-Induced Intravesical Pressure Elevation and Salivary Secretion in Mice(Pharmacology)
- The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: Ameliorative Effect of Solifenacin Succinate (Vesicare®), a Bladder-Selective Antimuscarinic Agent, on Overactive Bladder Symptoms, Especially Urge
- Relationship between the Functional Effect of Tamsulosin and Its Concentration in Lower Urinary Tract Tissues in Dogs(Pharmacology)
- Enzymologic and Pharmacologic Profile of Loxoprofen Sodium and Its Metabolites(Pharmacology)
- A Novel Vasopressin Dual V_/V_2 Receptor Antagonist, Conivaptan Hydrochloride, Improves Hyponatremia in Rats with Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH)(Pharmacology)
- Inhibitory Effects of Ramosetron, a Potent and Selective 5-HT_3-Receptor Antagonist, on Conditioned Fear Stress-Induced Abnormal Defecation and Normal Defecation in Rats : Comparative Studies With Antidiarrheal and Spasmolytic Agents
- Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats
- Evaluation of the Pharmacological Profile of Ramosetron, a Novel Therapeutic Agent for Irritable Bowel Syndrome
- The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction : Ameliorative Effect of Solifenacin Succinate (Vesicare^【○!R】), a Bladder-Selective Antimuscarinic Agent, on Overactive Bladder Symptoms, Especiall
- Tamsulosin Potently and Selectively Antagonizes Human Recombinant αA/D-Adrenoceptors : Slow Dissociation from the αA-Adrenoceptor May Account for Selectivity for αA-Adrenoceptor over αB-Adrenoceptor Subtype
- Tamsulosin Potently and Selectively Antagonizes Human Recombinant .ALPHA.1A/1D-Adrenoceptors: Slow Dissociation from the .ALPHA.1A-Adrenoceptor May Account for Selectivity for .ALPHA.1A-Adrenoceptor over .ALPHA.1B-Adrenoceptor Subtype
- Tacrolimus Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice: Implication of Interferon-.GAMMA. and Interleukin-1.BETA. Suppression